Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.

Outperform Votes

Underperform Votes

Community Sentiment

Pacira Biosciences has received 57.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Pacira Biosciences and other stocks. Vote “Outperform” if you believe PCRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Company Ownership

In the past three months, Pacira Biosciences insiders have sold 93.03% more of their company's stock than they have bought. Specifically, they have bought $91,250.00 in company stock and sold $176,140.00 in company stock.

Miscellaneous

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions

How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PCRX stock has increased by 38.0% and is now trading at $48.55. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

When is Pacira Biosciences' next earnings date?

How were Pacira Biosciences' earnings last quarter?

Pacira Biosciences Inc (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, May, 7th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.23. The company had revenue of $105.68 million for the quarter, compared to the consensus estimate of $101.64 million. Pacira Biosciences had a positive return on equity of 13.89% and a negative net margin of 0.02%. The firm's revenue for the quarter was up 15.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.22 EPS. View Pacira Biosciences' earnings history.

What price target have analysts set for PCRX?

15 analysts have issued 1 year price targets for Pacira Biosciences' shares. Their forecasts range from $41.00 to $85.00. On average, they expect Pacira Biosciences' share price to reach $54.50 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View analysts' price targets for Pacira Biosciences.

Has Pacira Biosciences been receiving favorable news coverage?

Headlines about PCRX stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacira Biosciences earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutPacira Biosciences.

Which major investors are selling Pacira Biosciences stock?

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Investments LP, Schroder Investment Management Group, Nuveen Asset Management LLC, Maverick Capital Ltd., Maverick Capital Ltd., Two Sigma Advisers LP, and UBS Group AG. Company insiders that have sold Pacira Biosciences company stock in the last year include David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, and Lauren Bullaro Riker. View insider buying and selling activity for Pacira Biosciences.

How do I buy shares of Pacira Biosciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacira Biosciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $48.55.

How big of a company is Pacira Biosciences?

Pacira Biosciences has a market capitalization of $2.04 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.